FRα-Targeted Antibody-Drug Conjugates for Selective Camptothecin Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments targeting folate receptor alpha (FRα) face challenges in effectively delivering cytotoxic payloads to cancer cells while minimizing off-target effects and maintaining stability and efficacy.

Innovation Solution

Development of antibody-drug conjugates (ADCs) that specifically bind to human FRα, utilizing a linker-conjugated camptothecin analogue, with an anti-FRα antibody construct and varying linker lengths, to enhance targeted delivery and intracellular accumulation of the drug.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If antibody-drug conjugates are designed to deliver cytotoxic payloads to cancer cells, then cytotoxicity against cancer cells is improved, but off-target effects increase

Engineering Contradiction:

Improvecytotoxic payload deliveryVSAvoidoff-target effects

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent uses a targeted delivery system where an antibody component specifically binds to folate receptor alpha on cancer cell surfaces, acting as an intermediary to deliver the cytotoxic camptothecin payload selectively to target cells while minimizing exposure to healthy tissues. This mediator approach resolves the contradiction by enabling high payload delivery to cancer cells without proportional off-target effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If linker length is varied to optimize drug delivery, then targeted delivery is improved, but manufacturing precision becomes more difficult

Engineering Contradiction:

Improveintracellular drug accumulationVSAvoidlinker conjugation consistency

Core Design Contradiction:

Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent systematically varies linker length parameters (different PEG chain lengths, spacer arm variations) to optimize the balance between targeted delivery efficiency and manufacturing feasibility. By establishing standardized conjugation protocols for different linker variants, the patent resolves the contradiction between achieving optimal intracellular accumulation and maintaining manufacturing precision.

Inventive Principle:

Principle #35Parameter changes

3Quantity of substance

If camptothecin analogues are used as payloads, then cytotoxicity is improved, but stability of the conjugate decreases

Engineering Contradiction:

Improvecytotoxic efficacyVSAvoidADC conjugate stability

Core Design Contradiction:

Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The patent creates composite structures combining camptothecin analogues with stabilized linker-antibody constructs. The composite design incorporates rigid spacers, controlled flexibility elements, and optimized attachment chemistries that maintain conjugate stability in circulation while enabling effective intracellular delivery and cytotoxic activation. This composite approach resolves the contradiction between payload potency and overall conjugate stability.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The ADCs demonstrate enhanced receptor-mediated internalization, improved cytotoxicity against FRα-expressing cancer cells, and sustained drug release, showing promising in vivo anti-tumor activity across various cancer models.

Implementation Method 1

The ADCs demonstrate enhanced receptor-mediated internalization

Methodology Applied

Scientific EffectReceptor-mediated internalization: Absorption (physical)

Implementation Method 2

sustained drug release, showing promising in vivo anti-tumor activity

Methodology Applied

Scientific EffectDrug release: Decomposition (biological)

Data Source

PatentUS12433952B2Antibody-drug conjugates targeting folate receptor alpha and methods of use

Publication Date: 2025.10.07 ZYMEWORKS BC INC

AI summary

Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.